{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458275232
| type              = mab
| image             = 
| alt               = 
| mab_type          = mab
| source            = u
| target            = [[Insulin-like growth factor 1 receptor|IGF-1R]]
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 905703-97-1
| ATC_prefix        = none
| ATC_suffix        = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CK1441RCZ8
| PubChem           = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          =
| C=6472 | H=10028 | N=1728 | O=2020 | S=42
| molecular_weight = 145.7 kg/mol
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| KEGG = D09908
}}

'''Ganitumab''' a human monoclonal antibody against type 1 insulin-like growth factor receptor ([[IGF1R]]), designed for the treatment of cancers.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab|publisher=[[American MedicaAssociation]]|url=http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf}}</ref>

Ganitumab was developed by [[Amgen]]. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.<ref>{{cite news|url=http://news.sciencemag.org/scienceinsider/2012/08/amgen-pulls-cancer-drug.html?ref=em |title=Amgen Pulls Cancer Drug |date=10 Aug 2012 |deadurl=yes |archiveurl=https://web.archive.org/web/20130723163332/http://news.sciencemag.org/scienceinsider/2012/08/amgen-pulls-cancer-drug.html?ref=em |archivedate=2013-07-23 |df= }}</ref><ref>{{cite news
 |url=http://www.istockanalyst.com/finance/story/5984012/amgen-amgn-terminates-ganitumab-pancreatic-cancer-trial 
 |title=Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial 
 |date=8 Aug 2012 
 |deadurl=yes 
 |archiveurl=https://web.archive.org/web/20120810222244/http://www.istockanalyst.com/finance/story/5984012/amgen-amgn-terminates-ganitumab-pancreatic-cancer-trial 
 |archivedate=2012-08-10 
 |df= 
}}</ref>

== References ==
<references/>

{{monoclonals for tumors}}
{{Growth factor receptor modulators}}

[[Category:Amgen]]
[[Category:Abandoned drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}